Phathom Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Capital | Deficit | Equity (Deficit) | |
| Balance at December 31, 2023 | 57,970,044 | $5 | 19 | $855,921 | $(928,685) | $(72,759) |
| 401(k) matching contribution | 93,736 | — | — | 712 | — | 712 |
| Vesting of restricted stock units | 340,542 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 5,626 | — | 5,626 |
| ESPP shares issued | 119,779 | — | — | 770 | — | 770 |
| Net loss | — | — | — | — | (82,852) | (82,852) |
| Balance at March 31, 2024 | 58,524,101 | $5 | 19 | $863,029 | $(1,011,537) | $(148,503) |
| Vesting of restricted stock units | 74,492 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 6,099 | — | 6,099 |
| Issuance of common stock from exercises of stock options | 2,432 | — | — | 21 | — | 21 |
| Net loss | — | — | — | — | (91,446) | (91,446) |
| Balance at June 30, 2024 | 58,601,025 | $5 | 19 | $869,149 | $(1,102,983) | $(233,829) |
| Balance at December 31, 2022 | 41,468,871 | $3 | 19 | $652,276 | $(727,093) | $(74,814) |
|---|---|---|---|---|---|---|
| 401(k) matching contribution | 52,130 | — | — | 456 | — | 456 |
| Vesting of restricted shares and restricted stock units | 414,119 | — | — | — | — | — |
| Stock-based compensation | — | — | — | 7,048 | — | 7,048 |
| ESPP shares issued | 121,801 | — | — | 856 | — | 856 |
| Issuance of common stock under ATM facility | 1,514,219 | 1 | — | 14,072 | — | 14,073 |
| Net loss | — | — | — | — | (37,814) | (37,814) |
| Balance at March 31, 2023 | 43,571,140 | $4 | 19 | $674,708 | $(764,907) | $(90,195) |
| Vesting of restricted shares and restricted stock units | 259,195 | — | — | 6 | — | 6 |
| Stock-based compensation | — | — | — | 7,253 | — | 7,253 |
| Issuance of common stock in connection with underwritten public offering, net | 12,793,750 | 1 | — | 141,389 | — | 141,390 |
| Issuance of common stock from exercises of stock options | 15,000 | — | — | 111 | — | 111 |
| Net loss | — | — | — | — | (40,965) | (40,965) |
| Balance at June 30, 2023 | 56,639,085 | $5 | 19 | $823,467 | $(805,872) | $17,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.